Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,528 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Computerized Tomography Clear all
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

NCT05031910
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Medical Device Usage and Evaluation, Best Practice, Resection
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
View directory record Official record
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint

NCT01705496
View directory record Official record
Conditions
Prosthetic Joint Infections
Interventions
[124I]FIAU
Radiation
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

NCT06906562
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
Drug · Procedure
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Patterns and Prevalence of FDG Extravasation in PET/CT Scans

NCT03041090
View directory record Official record
Conditions
Intravenous Infiltration
Interventions
Lucerno ID (identification) System
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

NCT03604315
View directory record Official record
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 1 Interventional

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217
View directory record Official record
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

NCT07275216
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Active, not recruiting No phase listed Observational

Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery

NCT04243447
View directory record Official record
Conditions
Femoracetabular Impingement
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 40 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 29, 2026, 5:59 AM EDT
Not listed Not applicable Interventional

Incidental Coronary Calcification Quality Improvement Project

NCT04789278
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Coronary Artery Disease
Interventions
Notification
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 29, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional

Glutamine PET Imaging Colorectal Cancer

NCT03275974
View directory record Official record
Conditions
RAS Wild Type, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography, Blood Draw
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07733674
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
203Pb-RMX-VHPIB injection, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Radiomedix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

NCT01004718
View directory record Official record
Conditions
Lymphoma
Interventions
Fludeoxyglucose F18, Computed Tomography, Positron emission tomography
Radiation · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 29, 2026, 5:59 AM EDT
Active, not recruiting Early Phase 1 Interventional

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

NCT06984861
View directory record Official record
Conditions
Oropharyngeal Carcinoma
Interventions
18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

NCT04965597
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

NCT00604461
View directory record Official record
Conditions
Mesothelioma
Interventions
Carboplatin, Bevacizumab and Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585
View directory record Official record
Conditions
Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions
Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 29, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

NCT00816335
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PET/CT scan, 18F-FDG Injection, Preoperative 18F-FDG PET/CT Scan, 18F-FDG for patients with Bladder Cancer, Surgical Procedure, Specimen PET/CT Scan
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 29, 2026, 5:59 AM EDT